Latest Breaking News On - Riovant - Page 1 : comparemela.com

Roivant: Oral Brepocitinib Fails To Meet Primary Endpoint In Phase 2 Study

Roivant (ROIV) and Priovant announced the Phase 2 study evaluating oral brepocitinib in adult patients with moderate to severe active lupus did not meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52.